Helicobacter pylori infection carrying the CagA gene may be associated with the diagnosis and disease progression of tuberculosis Authors: Fengyan Huang, Hao Zhan, Ying Yang, Liudan Liang, Qiuying Du, Caicun Huang, Jie Huang, Jiannan Lv Published: 2026 ABSTRACT Background and objectiveHelicobacter pylori (H. pylori) infection is associated with infectious diseases caused by pathogens such as Orientia tsutsugamushi (the causative agent of scrub typhus) and Brucella. However, the impact of H. pylori infection on tuberculosis (TB) remains unclear, and in particular, the clinical significance of infection with CagA-positive(CagA+) strains is worthy of exploration.MethodsA total of 120 TB patients clinically diagnosed at the Affiliated Hospital of Youjiang Medical University for Nationalities and the Fourth People’s Hospital of Nanning from June 2023 to December 2024 were selected as the observation group. The control group consisted of 130 healthy individuals who underwent physical examinations at the same hospitals during the same period, matched by gender, age, and place of residence. The subjects underwent serum H. pylori antibody detection and strain typing using the Western blot method.Result①The H. pylori infection rate was 67.5% in TB patients, slightly higher than 52.3% in healthy individuals, with no statistically significant difference(χ²=1.512, p = 0.219); however, the infection rate of the CagA+ strain was 51.7% in TB patients, significantly higher than 29.2% in healthy individuals(χ²=5.609, p = 0.018). ②The H. pylori infection rate was 76.2% in TB patients with more than two lesion sites, slightly higher than 57.9% in TB patients with a single lesion site, with no statistically significant difference(χ²=0.894, p = 0.345). However, the infection rate of CagA+ strains was 69.8% in TB patients with more than two lesion sites, significantly higher than 31.6% in TB patients with a single lesion site (χ² =5.575, p = 0.016). ③The H. pylori infection rate was 90.7% in retreated TB patients, higher than 54.5% in newly treated TB patients, with no statistically significant difference(χ²=3.036, p = 0.081). However, the infection rate of the CagA+ strain was 76.7% in retreated TB patients, significantly higher than 37.7% in newly treated TB patients (χ²=5.084, p = 0.024). ④The H. pylori infection rate was 79.8% in IGRA-positive (IGRA+)subjects, significantly higher than 42.6% in IGRA-negative (IGRA−) subjects(χ² =8.948, p = 0.003). Moreover, the infection rate of CagA+ strain was 62.3% in IGRA+ subjects, which was also significantly higher than 21.3% in IGRA− subjects (χ² =18.494, p = 0.001). ⑤Further multivariate regression analysis was conducted on the factors that might affect the onset of TB. The results showed that CagA+H. pylori infection (OR = 2.568; 95%CI: 1.223–5.387; χ²=6.216; p = 0.013) was independently associated with TB.ConclusionInfection with CagA gene-carrying H. pylori may facilitate the diagnosis of Mycobacterium tuberculosis infection and may influence the disease course of TB. Introduction Tuberculosis (TB) is a chronic infectious disease sustained by the bacterium Mycobacterium tuberculosis (M. tuberculosis) infection. More than one quarter of the world’s population is infected by M. tuberculosis, which generally affects the lungs but may also involve other organs [1]. After a host is infected with M. tuberculosis, only about 5% − 10% of subjects with primary M. tuberculosis infection may immediately manifest active tuberculosis (ATB), while the vast majority of other infected individuals commonly progresses into a latent tuberculosis infection (LTBI) [2]. Importantly, LTBI with normal immune function still have approximately a 5% − 10% chance of reactivating M. tuberculosis and will progress to having ATB disease over their lifetime [3]. When the host’s immune function declines, such as in cases of human immunodeficiency virus (HIV) infection, cancer, immunosuppressive therapy, and aging, the risk of these LTBI progressing to ATB increases [4]. Studies have shown that the immune response induced by M. tuberculosis is predominantly a T helper 1(Th1)-mediated pro-inflammatory response [5]. However, other studies have also indicated that compared with LTBI patients and non-infected individuals, the levels of Th1-type cytokines in TB patients are decreased, while the level of Interleukin−10 (IL−10) is increased [6]. Interferon-γ (IFN-γ) and Interleukin-17(IL-17) can induce the expression of chemokines, promote cell recruitment and granuloma formation, and play an important role in generating protective responses [7]. It is evident that the host’s immune status determines the heterogeneity of disease progression and disease spectrum after M. tuberculosis infection. Given that containment of M. tuberculosis relies on a balanced Th1/T helper 17(Th17)-driven protective response, while excessive regulatory or anti-inflammatory pathways can impair mycobacterial control, chronic co-infections capable of reshaping systemic immunity may influence TB outcomes. Helicobacter pylori (H. pylori) is a lifelong gastric colonizer that can induce durable immune modulation beyond the stomach. Therefore, it is plausible that high-virulence H. pylori could affect susceptibility to TB, disease progression, or reactivation from latent infection by altering host immune homeostasis. In parallel, chronic H. pylori infection can modulate immune conditions. H. pylori is a microaerophilic, Gram-negative pathogenic bacterium. Children are prone to H. pylori infection during childhood, and the bacterium can colonize their gastric mucosa for a lifetime. Early epidemiological studies on the relationship between H. pylori infection and respiratory diseases have been supported by animal model studies, which have shown that the microorganisms in the gastric chamber may be associated with lung injury, mainly manifested in the increased expression of inflammatory mediators and markers of endothelial dysfunction [8]. Persistent H. pylori infection has been reported to modulate Th1/Th17 responses and expand regulatory T cells (Tregs) on human samples and experimental models rather than TB-specific clinical cohorts [9, 10]. Additional evidence indicates that the colonization of H. pylori in mice promotes changes in their gut microbiota, the outbreak of inflammation, the reduction of innate immunity and the accumulation of activated T cells [11]. H. pylori containing the cytotoxin associated gene A (CagA) gene is referred to as a high-virulence strain, which can express Vacuolating Cytotoxin A (VacA) and CagA proteins [12]. Studies have shown that VacA exists in lung epithelial cells and can induce the production of interleukin-8 (IL-8) and interleukin-6 (IL-6) [13]. The absence of the CagA gene reduces the synthesis of IL-8 in airway epithelial cells of infants and adolescent [14]. In addition, compared to strains with the CagA−/VacA s2m2 genotype, strains with the CagA+/VacA s1m1 genotype are capable of inducing more robust immune and inflammatory responses [15]. All these changes indicate that the colonization of H. pylori can alter the host’s immunity, and the changes brought about by H. pylori strains carrying the CagA gene may be even greater. Studies have shown that H. pylori is closely associated with diseases caused by pathogens such as scrub typhus, HIV, Hepatitis C Virus (HCV) and Brucella spp [16–19]. Recent studies have confirmed that the human microbiome may play a role in regulating key aspects of TB, including its immune pathogenesis, treatment response, clinical outcomes, and prognosis [2]. Although existing basic research has confirmed that H. pylori has significant impacts on the immune response to M. tuberculosis and pulmonary pathology [20]. However, currently, clinical evidence regarding the interaction between the two is very limited, and the research conclusions are inconsistent [21–23]. Importantly, what remains unknown in human is whether H. pylori predisposes to TB infection and more severe clinical phenotypes or confers partial protection via immune modulation. Existing findings are difficult to reconcile because prior studies differ in populations and endpoints, and often apply heterogeneous H. pylori assays that do not distinguish current infection from past exposure. The strain-specific clinical relevance of CagA-positive(CagA+) H. pylori for TB in humans remains insufficiently defined. In summary, the reactivation of M. tuberculosis infection and disease progression are both controlled by host immunity, and persistent H. pylori infection exerts a significant impact on host immunity. Currently, there is still controversy over whether H. pylori exerts a positive or detrimental effect on immune alterations in TB patients, especially the role of CagA-carrying H. pylori in TB remains not fully understood. To this end, we designed this cross-sectional study to explore the effects of H. pylori infection, particularly infection with CagA-carrying H. pylori, on TB, with the aim of providing novel insights for clinical decision-making in TB patients. Materials and methods Study design and setting This was a hospital-based cross-sectional study conducted at the Affiliated Hospital of Youjiang Medical University for Nationalities and the Fourth People’s Hospital of Nanning. Participants were enrolled between June 2023 and December 2024. Sample size consideration This study used a convenience sample. All eligible TB inpatients during the study period were consecutively enrolled, and controls were recruited from health examination attendees during the same period. A slightly larger control group was included to increase the precision of seroprevalence estimates and to account for potential exclusions or missing data. No formal a priori sample size or power calculation was performed because the study was exploratory. General information A total of 120 patients with clinically diagnosed TB who were hospitalized in the Department of Infectious Diseases of the Affiliated Hospital of Youjiang Medical University for Nationalities and the Fourth People’s Hospital of Nanning from June 2023 to December 2024 were consecutively enrolled. Among them, there were 89 males and 31 females, the average age was 47.67 ± 10.57 years, 77 cases were treatment-naïve and 43 cases were recurrent, as shown in Fig. 1. The diagnosis of TB complies with the standards stipulated in the “Technical Guideline for Tuberculosis Prevention and Control in China (2021 Edition)” [24]. This study included pulmonary and extrapulmonary tuberculosis cases. Recurrent TB (retreated TB) was defined as patients with documented prior anti-TB treatment history who were re-diagnosed with TB during the current hospitalization, meeting the same diagnostic evidence requirements as treatment-naïve cases, including positive bacteriological tests, molecular tests, or histopathological confirmation together with compatible imaging findings. Inclusion criteria (for adults aged 18–60 years; at least one evidence): ①Bacteriological confirmation (positive smear and/or culture from respiratory specimens); ②Molecular confirmation (positive nucleic-acid amplification test); ③Histopathological confirmation consistent with TB; ④Presence of suspicious tuberculosis symptoms such as cough, expectoration, hemoptysis, weight loss, chest pain, fever, fatigue, loss of appetite, and night sweats, along with imaging findings suggestive of tuberculosis. Other pulmonary diseases were excluded by clinical evaluation and imaging. Exclusion criteria: ①Inability to provide informed consent due to mental or cognitive impairment; ②Age < 18 years or > 60 years; ③Pregnant or lactating women; ④Those with severe kidney or liver diseases, tumors, autoimmune diseases, and those using immunosuppressants, etc., whose immune function is downregulated. A total of 130 healthy individuals with matched gender and age who underwent physical examinations in the above-mentioned hospital during the same period were selected as the control group, including 88 males and 42 females, with an average age of 48.62 ± 9.72. Healthy individuals were recruited from attendees at the same hospitals during the same period. Controls were defined as individuals without current respiratory symptoms, without a self-reported history of TB or prior anti-TB treatment, and without known immunosuppressive conditions. Individuals with recent acute infection, chronic inflammatory diseases, malignancy, or long-term immunosuppressant use were excluded. As part of routine health screening, chest imaging and basic clinical evaluation were reviewed to exclude suspected active TB. The study protocol was approved by the ethics committee of the Affiliated Hospital of Youjiang Medical University for Nationalities and The Fourth People’s Hospital of Nanning. All patients were aware of the risks and benefits of participating in the project before the study began. They voluntarily participated in this research and have signed the relevant informed consent forms. Based on the H. pylori test results, all patients were divided into H. pylori positive cases and H. pylori negative cases. The general data comparison of the two groups of patients is detailed in Table 1. Fig. 1Study flow chart Study flow chart Table 1Comparison of general characteristics of tuberculosis patients with positive and negative H. pyloriCharacteristicsTuberculosis patients(n = 120)χ²/t-valuep-valueH. pylori(+)(n = 81)H. pylori(—)(n = 39)Gender [n, (%)]1.6960.193Male, [n (%)]63(77.8)26(66.7)Female, [n (%)]18(22.2)13(33.3)Age(± s, y)49.22 ± 8.9944.44 ± 12.790.8990.372Residency, [n, (%)]3.7610.052Rural(n = 98)70(86.4)28(71.8)Urban(n = 22)11(13.6)11(28.2)Interferon-Gamma Release Assay (IGRA) Result, [n, (%)]17.9020.001(+)(n = 88)69(85.2)19(48.7)(-)(n = 32)12(14.8)20(51.3)Infection site, [n, (%)]3.050.081≥ 247(58.0)16(41.0)134(42.0)23(59.0)Number oftreatments, [n, (%)]15.5490.001treatment-naïve(n = 77)43(53.1)35(89.7)recurrent(n = 43)38(47.0)4(10.3)(Bacille Calmette-Guérin) BCG vaccination, [n, (%)]1.7080.426Yes(n = 41)28(34.6)13(33.3)No(n = 71)46(56.8)25(64.1)Unknown(n = 8)7(8.6)1(2.6)Underlying diseases, [n, (%)]6.6410.036No31(38.3)17(43.6)(Acquired Immunodeficiency Syndrome) AIDS20(24.7)16(41.0)diabetes30(37.0)6(15.4)H. pylori [n(%)]Type I(n = 62)62(76.5)0Type Ⅱ(n = 19)19(23.5)0 Table 1Comparison of general characteristics of tuberculosis patients with positive and negative H. pyloriCharacteristicsTuberculosis patients(n = 120)χ²/t-valuep-valueH. pylori(+)(n = 81)H. pylori(—)(n = 39)Gender [n, (%)]1.6960.193Male, [n (%)]63(77.8)26(66.7)Female, [n (%)]18(22.2)13(33.3)Age(± s, y)49.22 ± 8.9944.44 ± 12.790.8990.372Residency, [n, (%)]3.7610.052Rural(n = 98)70(86.4)28(71.8)Urban(n = 22)11(13.6)11(28.2)Interferon-Gamma Release Assay (IGRA) Result, [n, (%)]17.9020.001(+)(n = 88)69(85.2)19(48.7)(-)(n = 32)12(14.8)20(51.3)Infection site, [n, (%)]3.050.081≥ 247(58.0)16(41.0)134(42.0)23(59.0)Number oftreatments, [n, (%)]15.5490.001treatment-naïve(n = 77)43(53.1)35(89.7)recurrent(n = 43)38(47.0)4(10.3)(Bacille Calmette-Guérin) BCG vaccination, [n, (%)]1.7080.426Yes(n = 41)28(34.6)13(33.3)No(n = 71)46(56.8)25(64.1)Unknown(n = 8)7(8.6)1(2.6)Underlying diseases, [n, (%)]6.6410.036No31(38.3)17(43.6)(Acquired Immunodeficiency Syndrome) AIDS20(24.7)16(41.0)diabetes30(37.0)6(15.4)H. pylori [n(%)]Type I(n = 62)62(76.5)0Type Ⅱ(n = 19)19(23.5)0 Comparison of general characteristics of tuberculosis patients with positive and negative H. pylori Number of treatments, [n, (%)] Definitions of key variables Multi-site infection “Multi-site infection” was operationally defined as TB lesions involving ≥ 2 anatomical sites on imaging. IGRA positivity IGRA was performed using T-SPOT according to the manufacturer’s instructions. IGRA positivity was defined as: ≥6 spots above the nil control. Methods Peripheral blood samples were collected from 120 TB patients and 130 healthy individuals undergoing physical examinations. H. pylori antibodies were detected by Western blotting (products from Shenzhen Bolaote Biological Co., LTD.). The reagents were purchased from Shenzhen Blot Bolaote Co., LTD. (production batch number: 161216), and the experimental operations were strictly carried out in accordance with the instructions. Western blotting can detect cytotoxin-associated gene A (CagA)(128 kD and 116 kD bands), Vacuolating toxin A (VacA)(95 kD and 91 kD bands), urease ureB(66 kD), and urease ureA(30 kD band) antibodies of H. pylori. Diagnostic criteria: (1) If either or both of urease A and urease B are positive, it can be diagnosed as H. pylori strain infection. (2) If condition (1) is met and CagA and/or VacA is positive, it can be diagnosed as CagA+ strain infection. (3) If condition (1) is met but CagA and/or VacA is negative, it is defined as CagA−strain infection. Western blot procedure and interpretation Peripheral venous blood (5 ml) was collected and serum was separated by centrifugation; aliquots were stored at − 80 °C until analysis, avoiding repeated freeze–thaw cycles. Serum H. pylori antibody detection and strain typing were performed using a commercial immunoblot kit (Shenzhen Bolaote Biological Co., LTD.; lot/batch no. 161216) according to the manufacturer’s instructions. Briefly, immunoblot strips pre-coated with H. pylori antigens were incubated with diluted serum (1:100) for 30 min at 37℃, washed three times, and then incubated with kit-provided secondary antibody. After washing, bands were visualized using the kit substrate and the strips were air-dried for interpretation. Criteria for positivity. Bands corresponding to CagA (128 kD and/or 116 kD), VacA (95 kD and/or 91 kD), urease UreB (66 kD), and urease UreA (30 kD) were interpreted as specified by the manufacturer. H. pylori infection was defined as positivity of UreA and/or UreB. Among H. pylori–positive subjects, CagA+ strain infection (type I) was defined as CagA and/or VacA positivity, whereas CagA− strain infection (type II) was defined as CagA and VacA negativity. For clarity, the terms “Type I” and “Type II” used in this manuscript do not represent internationally accepted or guideline-defined H. pylori strain classifications. Instead, they are operational categories defined by the Western blot assay employed in this study (Biolot Biotechnology Co., Shenzhen, China; CFDA-approved diagnostic kit). According to the manufacturer’s instructions, “Type I” denotes CagA and/or VacA seropositivity, whereas “Type II” denotes CagA−/VacA− seronegativity. Quality control and reproducibility. Each run included the kit-provided internal control bands to confirm assay validity. To minimize inter-assay variation, all samples were tested using the same kit lot and under identical laboratory conditions. Statistical methods The data were statistically analyzed using SPSS 19.0 statistical software. Count data were expressed as the number of cases and percentages, and the χ2 test was used for comparison. Continuous data were expressed as (x ± s), and the t-test was used for comparison. The analysis of influencing factors was conducted using logistic regression analysis. A P value < 0.05 was considered statistically significant. Missing data There were no missing data for variables used in the primary analyses and regression models. Assumptions for parametric tests Normality was evaluated using the Shapiro–Wilk test and visual inspection of histograms/Q–Q plots. Homogeneity of variances was assessed using Levene’s test when applicable. When distributional assumptions were not met, non-parametric tests (Mann–Whitney U) were used. Multivariable logistic regression and confounding control Multivariable logistic regression was used to estimate adjusted odds ratios (ORs) and 95% confidence intervals. Covariates were pre-specified a priori based on biological plausibility and prior evidence as potential confounders of the association between TB and H. pylori serostatus. The adjustment set included sex and age, residence, and BCG vaccination status. No automated stepwise selection was applied; all covariates were entered simultaneously. The dependent variable was TB case status. Model diagnostics included assessment of multicollinearity using variance inflation factors and evaluation of influential observations using standardized residuals and leverage values. Statistical significance was defined as two-sided P < 0.05. Results Infection status of H. pylori and CagA+H. pylori strains in the patients The H. pylori typing diagnosis was conducted on 120 TB patients and compared with 130 non-TB individuals undergoing physical examinations. The results showed that the H. pylori infection rate was 67.5% in TB patients, higher than 52.3% in healthy individuals, with no statistically significant difference(χ²=1.512, p = 0.219). However, the infection rate of CagA+strains was 51.7% in TB patients, significantly higher than the 29.2% in healthy individuals (χ²= 5.609, p = 0.018), as shown in Fig. 2a. The infection status of H. pylori in patients with TB involving a single site and more than two sites was analyzed. It was found that the infection rate of H. pylori in TB patients with two or more lesion sites was 76.2%, higher than 57.9% in TB patients with a single lesion site, with no statistically significant difference(χ² =0.894, p = 0.345). However, the infection rate of CagA+H. pylori in TB patients with more than two lesion sites was 69.8%, significantly higher than 31.6% in TB patients with a single lesion site (χ² =5.575, p = 0.016), as shown in Fig. 2b. The infection status of H. pylori in patients with treatment-naïve and recurrent TB was analyzed. It was found that the infection rate of H. pylori in patients with recurrent TB was 90.7%, higher than 54.5% in patients with treatment-naïve TB, with no statistically significant difference(χ²=3.036,p = 0.081). However, the infection rate of CagA+strains was 76.7% in patients with recurrent TB, significantly higher than 37.7% in patients with treatment-naïve TB (χ²=5.084, p = 0.024), as shown in Fig. 2c. The infection status of H. pylori in IGRA-positive(IGRA+) and IGRA-negative (IGRA−) individuals was analyzed. It was found that the infection rate of H. pylori was 79.8% in IGRA+ subjects, significantly higher than 42.6% in IGRA− subjects (χ²=8.948, p = 0.003). Moreover, the infection rate of CagA+strains in IGRA+ subjects was 62.3%, which was also significantly higher than 21.3% in IGRA− subjects (χ² =18.494, p = 0.001), as shown in Fig. 2d. Fig. 2a: lnfection status of H. pylori in tuberculosis patients versus healthy individuals. b: Infection status of H. pylori in tuberculosis patients with single-site and multi-site lesions. c: Prevalence of H. pylori infection in treatment-naive versus retreated tuberculosis patients. d: Infection status of H. pylori in IGRA+ and IGRA− subjects a: lnfection status of H. pylori in tuberculosis patients versus healthy individuals. b: Infection status of H. pylori in tuberculosis patients with single-site and multi-site lesions. c: Prevalence of H. pylori infection in treatment-naive versus retreated tuberculosis patients. d: Infection status of H. pylori in IGRA+ and IGRA− subjects Multiple regression analysis was conducted to explore the relationship between different types of H. pylori infection and TB A multivariable logistic regression model was fitted using the entire study sample (120 TB patients and 130 healthy controls). TB case status (TB = 1, control = 0) was set as the dependent variable, and sex, age, residence, BCG vaccination, and H. pylori infection type (type I vs. type II) were included as covariates. The results showed that CagA+H. pylori infection (OR = 2.568; 95%CI: 1.223–5.387; χ²=6.216; p = 0.013) was independently associated with the occurrence of TB. Details are shown in Table 2. Table 2Multivariable logistic regression for factors associated with TB case status (TB patients vs. healthy controls)VariableβcoefficientStandard errorWald x2p-valueOR(95% CI)Sex(male/female)0.1700.3100.3000.5840.646–2.176Residency (Rural/Urban)0.1800.3500.2630.6080.602–2.378Age(< 44)/44ཞ59/≥60)0.2600.8200.1000.7520.260–6.463BCG vaccination-0.4330.4950.3820.6490.246–1.711 H. pylori (typeI/typeII)0.9430.3786.2160.0131.223–5.387BCG vaccination: Bacille Calmette-Guérin vaccine Table 2Multivariable logistic regression for factors associated with TB case status (TB patients vs. healthy controls)VariableβcoefficientStandard errorWald x2p-valueOR(95% CI)Sex(male/female)0.1700.3100.3000.5840.646–2.176Residency (Rural/Urban)0.1800.3500.2630.6080.602–2.378Age(< 44)/44ཞ59/≥60)0.2600.8200.1000.7520.260–6.463BCG vaccination-0.4330.4950.3820.6490.246–1.711 H. pylori (typeI/typeII)0.9430.3786.2160.0131.223–5.387BCG vaccination: Bacille Calmette-Guérin vaccine Multivariable logistic regression for factors associated with TB case status (TB patients vs. healthy controls) Sex (male/female) Age (< 44)/44ཞ59/≥60) H. pylori (typeI/typeII) BCG vaccination: Bacille Calmette-Guérin vaccine Discussion It is known that both H. pylori and M. tuberculosis can infect children, adolescents and adults. The peak of H. pylori infection occurs in the earliest years of life. In fact, in endemic areas, most children are infected with the bacterium through family members before the age of two [25]. The risk of M. tuberculos infection peaks during adolescence and young adulthood [26]. Importantly, when the first pathogen has sufficient time to colonize the host and has developed a certain degree of chronic infection before the host is exposed to the second pathogen, the mutual impact of the two bacteria on each other tends to be more significant [20]. At present, the evidence regarding the interaction between M. tuberculosis and H. pylori species is extremely limited, whether from human observational studies or other experimental research. The existing basic research only focuses on the impact of H. pylori on the immune response and pulmonary pathology of M. tuberculosis [20]. In our research, we focused on H. pylori strains carrying the CagA gene and systematically explored their association with the clinical phenotypes of M. tuberculosis infection, providing a new perspective for analyzing their interaction. In this research, we found no statistically significant difference in the H. pylori infection rate between TB patients and healthy individuals undergoing physical examinations (67.5% vs. 52.3%, P > 0.05). This is consistent with the research of Sanaka et al. [22]. However, the research results of Perry [23] and Jingjing Pan et al. [21] found that the H. pylori infection rate in TB patients was higher than that in healthy individuals undergoing physical examinations. The differences in these results may be related to the sample size and the influence of environmental factors, regions and living habits on H. pylori infection. However, an observational study on family contacts of TB patients showed that the infection rate of H. pylori among those who developed TB during the 2-year follow-up period was significantly lower than that among those who did not develop the disease. The study also found that cynomolgus monkeys naturally infected with H. pylori had a lower probability of progressing to TB 6–8 months after experimental M. tuberculosis attack, jointly suggesting that H. pylori may have a protective effect against tuberculosis [27]. The mechanism underlying the protective effect of H. pylori against TB is not fully understood. It is speculated that the possible mechanisms include: (1) H. pylori infection in childhood can permanently differentiate naive T cells into the Th1 phenotype and induce high levels of Treg cells both locally and systemically7. Exposure to infections during childhood helps activate and regulate innate and adaptive immune responses, thereby providing protection against atopic, allergic and autoimmune diseases. This is the main content of the “hygiene hypothesis” [28]. Based on this, it is speculated that H. pylori infection during childhood may enhance immune defense against M. tuberculosis infection by promoting the development of the host’s immune system. (2)H. pylori colonization may induce the bystander effect through persistent inflammation and T-cell signal transduction induced by chronic mucosal infection, thereby enhancing the innate immune response to other infectious diseases. ⑶H. pylori infection mainly induces the Th1/Th17 response. The IL-17 induced may trigger T cells to recruit to the lungs, enhancing the host’s initial inhibition of M. tuberculosis reproduction. In this research, we used Western blotting to identify the strains of H. pylori infection and analyzed the relationship between infection with different virulence strains and TB. It was found that CagA+ (carrying the CagA gene) H. pylori infection is closely related to the onset of TB, recurrent TB and multiple infections. Moreover, multiple regression analysis suggests that CagA+H. pylori infection is independently associated with the onset of TB. The synergistic effect of CagA+H. pylori on the occurrence and development of TB that we observed contradicts the research results of Perry et al.27. However, the results of two independent mouse M. tuberculosis infection experiments showed that Helicobacter hepaticus, which naturally colonizes the cecum, colon and biliary tract of mice, exacerbates M. tuberculosis-induced lung pathological damage [29, 30]. The mechanisms causing lung injury are mainly related to the outbreak of inflammation, uncontrolled innate immunity, and the rapid accumulation of activated T cells in the lungs [29]. These basic research conclusions further support our findings. In fact, previous research has confirmed that for the majority of people, H. pylori may be beneficial during childhood, but its effect may be the opposite in adulthood [31]. Our current research findings suggest that infection with CagA+ high-virulence strains of H. pylori may be related to the progression of TB by weakening the immune defense function of TB patients. The potential mechanisms include: (1)The direct immunosuppressive effects of VacA and CagA proteins: On the one hand, VacA protein inhibits T cell proliferation by inducing G1/S phase arrest of T cells; on the other hand, it down-regulates Interleukin-2(IL-2) transcription by interfering with the T cell receptor (TCR) /IL-2 signaling pathway [32]; whereas the CagA protein can effectively inhibit the proliferation of B cells [33]. (2)Proliferation and immunosuppression of regulatory Tregs: ①Animal model studies have shown that in 7-day-old mice, the VacA protein acts on dendritic cells and macrophages, promoting Tregs differentiation rather than Th17 cells, and inducing the emergence of peripheral Tregs populations in the lungs; however, no similar phenomenon was observed in 6-week-old mice, suggesting age-dependent immune regulation differences [34]. ②The clinical studies have shown that blocking the recruitment of Treg cells to the liver can reverse the harmful effects of H. pylori on the immune control of M. tuberculosis bovis [20]. ③The impact of gastrointestinal microbiota dysbiosis on systemic immunity: H. pylori infection can alter the composition of gastrointestinal microbiota by regulating gastric acid secretion, influencing the expression of antimicrobial peptides, and releasing virulence factors. These changes may disrupt the gut-lung immune axis and further weaken the host’s defense against TB [35]. Subsequently, we further explored the relationship between H. pylori infection and IGRA results. The results showed that the infection rates of CagA+ strains and H. pylori in IGRA+ subjects were significantly higher than those in IGRA− subjects. In fact, H. pylori infection induced a strong Th1 response in animal hosts (i.e., CD4 + T cells expressing IFN-γ or Tumor Necrosis Factor-α(TNF-α)), and additionally induced Th17 cells expressing IL-17. An interesting phenomenon has also been observed in terms of CD4+ T cell multifunctionality. The dominant CD4+ T cell population in the stomach infected with H. pylori only expresses TNF-α, IL-17 or TNF-α combined with IFN-γ, and did not express IL-10 [20]. We speculate that the sustained and intense Th1-reactive CD4+ T cells induced by H. pylori infection promote the production of IFN-γin response to tuberculosis-specific antigens. A cross-sectional study conducted by Perry et al. also found that CagA+H. pylori infection was associated with an enhanced Th1-like response (particularly elevated IFN-γ levels) to tuberculosis antigens [27]. Further research by Perry et al. indicated that even in individuals co-infected with helminths(which typically tend to induce Th2 responses), H. pylori was still associated with an enhanced Th1 response to tuberculosis antigens [23]. In conclusion, infection with CagA+H. pylori strains is not only independently associated with the onset of tuberculosis, but also associated with the recurrence and dissemination of tuberculosis. In addition, the infection rate of CagA+H. pylori was significantly higher in IGRA+ patients than in IGRA− patients, suggesting that H. pylori infection carrying the CagA gene may be have potential value as an marker for the diagnosis of TB. In the clinical management of TB patients, high attention should be paid to the infection status of the CagA+H. pylori strain, which may provide new strategies for the diagnosis and treatment of TB. Prospective multicenter studies with standardized diagnostics, strain-level confirmation, comprehensive confounder control, and external validation are needed to assess reproducibility and potential clinical value. This research may have some limitations. Firstly, this research uesd Western blotting to detect serum H. pylori antibodies and classify H. pylori infections, which is a simple method with high specificity and sensitivity. However, serological studies were prone to data deviations, and we did not adopt both detection methods to reduce diagnostic errors. Secondly, our data analysis was limited to serological tests. This research also did not analyze some factors that might affect H. pylori infection, such as whether it was a current infection, family income, educational level, and antibiotic use. Therefore, it is necessary to further conduct multi-center prospective cohort studies, combine two or more detection methods, especially those that are beneficial for identifying current infections, incorporate multi-dimensional confounding factor analysis, data integration, and multi-omics analysis, etc., to deeply explore the relevant immune mechanisms, verify the research results, and address the deficiencies of the above-mentioned studies.